Table 1 Summary of the clinical characteristics of the patient groups included in the discovery cohort
Chemoresistant with TFIp < 6 m (n = 7) | Chemosensitive with TFIp > 6 m (n = 7) | Chemosensitive with no recurrence (n = 7) | |
|---|---|---|---|
Age (years) | |||
Average (range) | 67 (53–77) | 58 (49–69) | 60 (43–70) |
Menopausal status (n, %) | |||
Premenopausal | 0 | 2 (29%) | 1 (14%) |
Postmenopausal | 7 (100%) | 5 (71%) | 6 (86%) |
Stage (n, %) | |||
IIIC | 6 (86%) | 6 (86%) | 7 (100%) |
IV | 1 (14%) | 1 (14%) | 0 |
Serum CA125 levels at diagnosis (U/mL) | |||
Average (range) | 1944 (809–5500) | 2444 (126–6992) | 1051 (100–2856) |
TFIp (months) | |||
Average (range) | 3 (1–5) | 28 (11–67) | NA |
Primary treatment (n, %) | |||
Cytoreductive surgery | 4 (57%) | 5 (71%) | 4 (57%) |
Neoadjuvant chemotherapy | 3 (43%) | 2 (29%) | 3 (43%) |
Status (n, %) | |||
Alive | 0 | 1 (14%) | 7 (100%) |
Dead | 7 (100%) | 6 (86%) | 0 |